← All trials
NCT05479136
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 24, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jul 29, 2022
- Last posted
- Oct 27, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ArizonaLead sponsor
- Blue Earth DiagnosticsCollaborator
- University of ArizonaSponsor investigator
- Barrow Neurological InstituteCollaborator
- Barrow Neurological InstituteOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.